ProShares Ultra Bloomberg Natural Gas

United States Natural Gas

MicroSectors Gold Miners 3X Leveraged ETN

Direxion Daily TSLA Bull 1.5X Shares

Direxion Daily Gold Miners Bull 3X ETF

ProShares Ultra Silver

GraniteShares 1.25x Long Tesla Daily ETF

Direxion Daily FTSE China Bull 3X ETF

Altimmune Inc. Common Stock

Global X Silver Miners ETF

ProShares UltraShort Bloomberg Natrl Gas

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

T-REX 2X Inverse Tesla Daily Target ETF

Direxion Daily Gold Miners Bear 3X ETF

ProShares UltraShort Silver

Volatility Shares Trust 2x Ether ETF

iShares Ethereum Trust ETF

GraniteShares 2x Long AMZN Daily ETF

VS TR 2x Long VIX Futures ETF

Direxion Daily 20+ Yr Trsy Bull 3X ETF

BloomZ Inc. Ordinary Shares

Siyata Mobile Inc. Common Shares

Neuraxis Inc. Common Stock

TNL Mediagene Ordinary Shares

Edible Garden AG Incorporated Common Stock

Eyenovia Inc. Common Stock

D-Wave Quantum Inc. Common Shares

Click Holdings Limited Ordinary Share

Mind Medicine (MindMed) Inc. Common Shares

Pony AI Inc. American Depositary Shares

Protagenic Therapeutics Inc. Common Stock

NWTN Inc. Class B Ordinary Shares

ASP Isotopes Inc. Common Stock

New Fortress Energy Inc. Class A Common Stock

Canaan Inc. American Depositary Shares

Eagle Materials Inc Common Stock

Classover Holdings Inc. Class B Common Stock

Hyperscale Data Inc. Common Stock

MicroAlgo Inc. Ordinary Shares

Freight Technologies Inc. Ordinary Shares

Click here to get full coverage on How Vir CEO Marianne De Backer Is Rebuilding Commercial Momentum - insights.citeline.com

How Vir CEO Marianne De Backer Is Rebuilding Commercial Momentum  insights.citeline.com

How Vir CEO Marianne De Backer Is Rebuilding Commercial Momentum - insights.citeline.com

Click here to get full coverage on Vir Biotechnology (VIR) PT Lowered to $15 at H.C. Wainwright - StreetInsider

Vir Biotechnology (VIR) PT Lowered to $15 at H.C. Wainwright  StreetInsider

Vir Biotechnology (VIR) PT Lowered to $15 at H.C. Wainwright - StreetInsider

Click here to get full coverage on Vir Biotechnology (VIR) Price Target Slashed Amid Clinical Trial Results | VIR Stock News - GuruFocus

Vir Biotechnology (VIR) Price Target Slashed Amid Clinical Trial Results | VIR Stock News  GuruFocus

Vir Biotechnology (VIR) Price Target Slashed Amid Clinical Trial Results | VIR Stock News - GuruFocus

Click here to get full coverage on Vir Biotechnology’s SWOT analysis: HDV treatment potential lifts stock outlook - Investing.com

Vir Biotechnology’s SWOT analysis: HDV treatment potential lifts stock outlook  Investing.com

Vir Biotechnology’s SWOT analysis: HDV treatment potential lifts stock outlook - Investing.com

Click here to get full coverage on Vir Biotechnology price target lowered to $15 from $110 at H.C. Wainwright - TipRanks

Vir Biotechnology price target lowered to $15 from $110 at H.C. Wainwright  TipRanks

Vir Biotechnology price target lowered to $15 from $110 at H.C. Wainwright - TipRanks

Click here to get full coverage on Vir's 'functional cure' candidate for hepatitis B misses mark in phase 2 - Fierce Biotech

Vir's 'functional cure' candidate for hepatitis B misses mark in phase 2  Fierce Biotech

Vir's 'functional cure' candidate for hepatitis B misses mark in phase 2 - Fierce Biotech

Click here to get full coverage on 7@four goes live from VIR HyperFest - WDBJ

7@four goes live from VIR HyperFest  WDBJ

7@four goes live from VIR HyperFest - WDBJ

Click here to get full coverage on The Taste by Vir Sanghvi: As Ozempic arrives in India, eating habits will change, which is bad news for restaurants - Hindustan Times

The Taste by Vir Sanghvi: As Ozempic arrives in India, eating habits will change, which is bad news for restaurants  Hindustan Times

The Taste by Vir Sanghvi: As Ozempic arrives in India, eating habits will change, which is bad news for restaurants - Hindustan Times

Click here to get full coverage on Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025 - Business Wire

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025  Business Wire

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025 - Business Wire

Click here to get full coverage on VIR presents HyperFest to open the 2025 season - WFIR News

VIR presents HyperFest to open the 2025 season  WFIR News

VIR presents HyperFest to open the 2025 season - WFIR News

Click here to get full coverage on Vir’s hepatitis B combo falls short in Phase II trial - MSN

Vir’s hepatitis B combo falls short in Phase II trial  MSN

Vir’s hepatitis B combo falls short in Phase II trial - MSN

Click here to get full coverage on Vir enrols first subject in Phase III programme to assess CHD therapy - Clinical Trials Arena

Vir enrols first subject in Phase III programme to assess CHD therapy  Clinical Trials Arena

Vir enrols first subject in Phase III programme to assess CHD therapy - Clinical Trials Arena

Click here to get full coverage on Vir Leans Into Immunology Roots After Flamed-Out COVID Fame - BioSpace

Vir Leans Into Immunology Roots After Flamed-Out COVID Fame  BioSpace

Vir Leans Into Immunology Roots After Flamed-Out COVID Fame - BioSpace

Click here to get full coverage on Vir Biotechnology stock target cut to $15 by H.C. Wainwright - Investing.com India

Vir Biotechnology stock target cut to $15 by H.C. Wainwright  Investing.com India

Vir Biotechnology stock target cut to $15 by H.C. Wainwright - Investing.com India

Click here to get full coverage on 7@four Goes Live from VIR HyperFest Part 1 - WDBJ

7@four Goes Live from VIR HyperFest Part 1  WDBJ

7@four Goes Live from VIR HyperFest Part 1 - WDBJ

Click here to get full coverage on Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results  Business Wire

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire

Click here to get full coverage on Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results - Business Wire

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results  Business Wire

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results - Business Wire

Click here to get full coverage on Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 - Business Wire

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025  Business Wire

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 - Business Wire

Click here to get full coverage on Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance

Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...  Yahoo Finance

Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance

Click here to get full coverage on Vir Das takes a dig at Cannes Film Festival's ban on nudity and voluminous outfits: ‘Planned 78 foot long piece’ - Hindustan Times

Vir Das takes a dig at Cannes Film Festival's ban on nudity and voluminous outfits: ‘Planned 78 foot long piece’  Hindustan Times

Vir Das takes a dig at Cannes Film Festival's ban on nudity and voluminous outfits: ‘Planned 78 foot long piece’ - Hindustan Times

Click here to get full coverage on Aaron Link: 1:47.7 at VIR Full Course, 2:32.3 at VIR Grand Course - GM News

Aaron Link: 1:47.7 at VIR Full Course, 2:32.3 at VIR Grand Course  GM News

Aaron Link: 1:47.7 at VIR Full Course, 2:32.3 at VIR Grand Course - GM News

Click here to get full coverage on Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta - Business Wire

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta  Business Wire

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta - Business Wire

Click here to get full coverage on Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta  Business Wire

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire

Click here to get full coverage on Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple - Yahoo Finance

Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple  Yahoo Finance

Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple - Yahoo Finance

Click here to get full coverage on VIR Instrument - NASA Science (.gov)

VIR Instrument - NASA Science (.gov)

Click here to get full coverage on Vir Biotech at BofA Conference: Strategic Focus on Immune System - Investing.com

Vir Biotech at BofA Conference: Strategic Focus on Immune System  Investing.com

Vir Biotech at BofA Conference: Strategic Focus on Immune System - Investing.com

Click here to get full coverage on Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq

Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates  Nasdaq

Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq

Click here to get full coverage on Vir Das's LOL Post After Cannes Bans Nudity On Red Carpet: "If I Can't Wear A Gota Original..." - NDTV

Vir Das's LOL Post After Cannes Bans Nudity On Red Carpet: "If I Can't Wear A Gota Original..."  NDTV

Vir Das's LOL Post After Cannes Bans Nudity On Red Carpet: "If I Can't Wear A Gota Original..." - NDTV

Click here to get full coverage on Vir, awaiting 'functional cure' data for hep B combo, won't take treatment forward alone - Fierce Biotech

Vir, awaiting 'functional cure' data for hep B combo, won't take treatment forward alone  Fierce Biotech

Vir, awaiting 'functional cure' data for hep B combo, won't take treatment forward alone - Fierce Biotech

Click here to get full coverage on Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts  simplywall.st

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st

Click here to get full coverage on Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results - PR Newswire

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results  PR Newswire

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results - PR Newswire

Click here to get full coverage on 2025 Chevy Corvette ZR1 Topples the McLaren Senna's VIR Lap Time - Car and Driver

2025 Chevy Corvette ZR1 Topples the McLaren Senna's VIR Lap Time  Car and Driver

2025 Chevy Corvette ZR1 Topples the McLaren Senna's VIR Lap Time - Car and Driver

Click here to get full coverage on Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company - Yahoo Finance

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company  Yahoo Finance

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company - Yahoo Finance

Click here to get full coverage on Earnings Outlook For Vir Biotechnology - Nasdaq

Earnings Outlook For Vir Biotechnology  Nasdaq

Earnings Outlook For Vir Biotechnology - Nasdaq

Click here to get full coverage on Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Finance

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results  Yahoo Finance

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Finance

Click here to get full coverage on Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study - Yahoo Finance

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study  Yahoo Finance

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study - Yahoo Finance

Click here to get full coverage on Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint - Yahoo Finance

Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint  Yahoo Finance

Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint - Yahoo Finance

Click here to get full coverage on Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC - Business Wire

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC  Business Wire

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC - Business Wire

Click here to get full coverage on Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance

Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...  Yahoo Finance

Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance

Click here to get full coverage on Vir’s hep B disappointment, Ipsen's new Iqirvo data, plus more from #EASL25 - Endpoints News

Vir’s hep B disappointment, Ipsen's new Iqirvo data, plus more from #EASL25  Endpoints News

Vir’s hep B disappointment, Ipsen's new Iqirvo data, plus more from #EASL25 - Endpoints News

Click here to get full coverage on Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment - Seeking Alpha

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment  Seeking Alpha

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment - Seeking Alpha

Click here to get full coverage on Lobbying Update: $50,000 of VIR BIOTECHNOLOGY INC. lobbying was just disclosed - Nasdaq

Lobbying Update: $50,000 of VIR BIOTECHNOLOGY INC. lobbying was just disclosed  Nasdaq

Lobbying Update: $50,000 of VIR BIOTECHNOLOGY INC. lobbying was just disclosed - Nasdaq

Click here to get full coverage on Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer - Barron's

Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer  Barron's

Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer - Barron's

Click here to get full coverage on Vir’s early T cell engager data offer first look at cancer pivot, stock jumps - Endpoints News

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps  Endpoints News

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps - Endpoints News

Click here to get full coverage on Vir announces 24-week post-end of treatment data for Hep B therapy - MSN

Vir announces 24-week post-end of treatment data for Hep B therapy  MSN

Vir announces 24-week post-end of treatment data for Hep B therapy - MSN

Click here to get full coverage on Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 1c - StreetInsider

Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 1c  StreetInsider

Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 1c - StreetInsider

Click here to get full coverage on Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference  Business Wire

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire

Click here to get full coverage on Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Business Wire

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025  Business Wire

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Business Wire

Click here to get full coverage on Implementation plan next for revised PDP8 - Vietnam Investment Review - VIR

Implementation plan next for revised PDP8  Vietnam Investment Review - VIR

Implementation plan next for revised PDP8 - Vietnam Investment Review - VIR

Click here to get full coverage on Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Business Wire

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update  Business Wire

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Business Wire

Click here to get full coverage on 2025 VIR event schedule adds new veteran event, brings back superbikes - YourGV.com

2025 VIR event schedule adds new veteran event, brings back superbikes  YourGV.com

2025 VIR event schedule adds new veteran event, brings back superbikes - YourGV.com

Click here to get full coverage on Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - Business Wire

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program  Business Wire

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - Business Wire

Click here to get full coverage on Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment - Investor's Business Daily

Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment  Investor's Business Daily

Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment - Investor's Business Daily

Click here to get full coverage on Vir's stock climbs after masked cell therapies show early signs of success in cancer - FirstWord Pharma

Vir's stock climbs after masked cell therapies show early signs of success in cancer  FirstWord Pharma

Vir Biotechnology Inc (VIR)

Price Chart

Key Statistics

Technicals

About VIR

Latest News

How Vir CEO Marianne De Backer Is Rebuilding Commercial Momentum - insights.citeline.com

Vir Biotechnology (VIR) PT Lowered to $15 at H.C. Wainwright - StreetInsider

Vir Biotechnology (VIR) Price Target Slashed Amid Clinical Trial Results | VIR Stock News - GuruFocus

Advanced Charts

Top Gainers

Top Losers